Pyxis Oncology (PYXS)
NASDAQ:PYXS
Total Valuation
Pyxis Oncology has a market cap or net worth of $92.99M. The enterprise value is $96.24M.
Market Cap$92.99M
Enterprise Value$96.24M
Share Statistics
Pyxis Oncology has 62,831,245 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,831,245
Owned by Insiders10.26%
Owned by Institutions32.83%
Financial Efficiency
Pyxis Oncology’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -117.12%.
Return on Equity (ROE)-1.49
Return on Assets (ROA)-0.87
Return on Invested Capital (ROIC)-117.12%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee314.95K
Profits Per Employee-1.81M
Employee Count44
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Pyxis Oncology is ―. Pyxis Oncology’s PEG ratio is 0.30.
PE Ratio―
PS Ratio5.16
PB Ratio1.34
Price to Fair Value1.34
Price to FCF-1.13
Price to Operating Cash Flow-1.45
PEG Ratio0.30
Income Statement
In the last 12 months, Pyxis Oncology had revenue of 13.86M and earned -79.62M in profits. Earnings per share was -1.28.
Revenue13.86M
Gross Profit11.47M
Operating Income-84.42M
Pretax Income-78.23M
Net Income-79.62M
EBITDA-79.91M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -63.50M and capital expenditures -9.00K, giving a free cash flow of -63.51M billion.
Operating Cash Flow-63.50M
Free Cash Flow-63.51M
Free Cash Flow per Share-1.01
Dividends & Yields
Pyxis Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.27
52-Week Price Change54.17%
50-Day Moving Average1.47
200-Day Moving Average2.12
Relative Strength Index (RSI)50.70
Average Volume (3m)757.02K
Important Dates
Pyxis Oncology upcoming earnings date is May 8, 2026, Before Open (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateMay 8, 2026
Ex-Dividend Date―
Financial Position
Pyxis Oncology as a current ratio of 3.41, with Debt / Equity ratio of 34.96%
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap0.26
Net Debt to EBITDA-0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Pyxis Oncology has paid 1.39M in taxes.
Income Tax1.39M
Effective Tax Rate-0.02
Enterprise Valuation
Pyxis Oncology EV to EBITDA ratio is -0.94, with an EV/FCF ratio of -1.18.
EV to Sales5.39
EV to EBITDA-0.94
EV to Free Cash Flow-1.18
EV to Operating Cash Flow-1.18
Balance Sheet
Pyxis Oncology has $66.86M in cash and marketable securities with $18.67M in debt, giving a net cash position of $48.18M billion.
Cash & Marketable Securities$66.86M
Total Debt$18.67M
Net Cash$48.18M
Net Cash Per Share$0.77
Tangible Book Value Per Share$0.86
Margins
Gross margin is 103.12%, with operating margin of -609.18%, and net profit margin of -574.55%.
Gross Margin103.12%
Operating Margin-609.18%
Pretax Margin-564.55%
Net Profit Margin-574.55%
EBITDA Margin-576.63%
EBIT Margin-609.18%
Analyst Forecast
The average price target for Pyxis Oncology is $6.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.25
Price Target Upside322.30% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-82.53%
EPS Growth Forecast-52.00%